SOURCE: Real Endpoints

Real Endpoints

November 29, 2011 10:07 ET

Real Endpoints Launches New Reimbursement-Focused Information Service

Value & Innovation to Provide Review and Analysis of the Reimbursement Environment to Payers, Providers and Product Companies

WESTPORT, CT--(Marketwire - Nov 29, 2011) - Real Endpoints LLC, a new information company focused on healthcare reimbursement, announced today the launch of its Value & Innovation LLC ( business -- with the Value & Innovation Blog as its first initiative.

The V&I blog ( will provide pointed, strategic commentary on the reimbursement environment facing drug and device companies, payers and at-risk providers. Despite the fact that these groups are collectively making billions of dollars of decisions on how to position, price and reimburse their products and services, relatively few are based on real assessment of value and risk -- in part because there are few credible sources of information on which these players can rely.

"We see a huge need to help payers, at-risk providers and drug, device and diagnostic companies understand how and where reimbursement pressures are changing and what kind of evidence they need to demonstrate the value of their products and services," said Real Endpoints CEO Roger Longman, the co-founder and former managing director of Windhover Information. "V&I, and the V&I Blog, will help to fill that gap."

"The fact that so many recent pharmaceutical product launches have dramatically underperformed financial expectations is testament to the confusion about reimbursement," he continued. "And this confusion is also choking off innovation as investment in new technology declines -- something we cannot afford given healthcare's economic crisis. One solution is to provide the pertinent information companies can use to prove value and which payers can use to assess it."

The V&I Blog will be free, with new posts issued several times a week.

Key to its value will be its credibility, noted Real Endpoints Chairman Norman Selby, the former head of McKinsey & Co.'s pharmaceutical practice. "The payer and product industries face many of the same issues, but approach them virtually as antagonists. The information one side provides is always treated skeptically by the other. At Value & Innovation, and the V&I Blog, we'll provide strategically sophisticated data, analysis and insight -- but objectively."

Contributing to V&I, and to the V&I blog, will be Ellen Licking, a senior editor at V&I and a former senior editor at Elsevier Business Intelligence (EBI); and V&I Contributing Editor Melanie Senior, who is responsible for European biopharma content at EBI.

Over the next several months, V&I will be launching a number of services, including a research/advisory program, topical reports, and conferences and webinars.

About Real Endpoints
Real Endpoints ( is a new company building a uniquely objective and credible information platform to reveal insights about the changing world of reimbursement at the critical intersection between payers, providers, and medical product developers. RE's business portfolio includes Reimbursement Intelligence, a market-research company focused on managed markets; Value & Innovation, a new research analytics and information service; and several proprietary databases in development.

Contact Information